Atlas Trials

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Clinical trial NCT07436390 · COMPLETED

Trial details

NCT number
NCT07436390
Sponsor
Institute of Oncology Ljubljana
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Metastatic MelanomaMalignant MelanomaSkin Cancer
Start date
2024-03-31
Primary completion
2024-03-31
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.